Oncology is currently a more cutting-edge, dynamic field than it has ever been – as demonstrated at this year’s American Society of Clinical Oncology (ASCO) conference.
Greater patient involvement is among the stated aims of the ABPI, so why do companies up and down the country say the association’s Code of Conduct makes engagement difficult?
Over the years, many hands have been wrung over clinical trial recruitment – low participation rates are common and can bring down studies before they even get a chance to begin.
To have any impact, patient engagement needs to start with the drug development pathway, not at the point of licensing. That’s especially true in the rare disease space, where the unme
For years, digital health has been heralded as the saviour of health services and the answer to patient engagement. Now the conversation is changing from what technology can do, to wha